Financial Results Highlights | | GAAP Results | | | | | --- | --- | --- | --- | --- | | | | Q3 2025 | | Q3 2024 | | Revenue (millions) | $| 653.0 |$ | 649.7 | | Gross margin | | 52.6 % | | 54.8 % | | Income from operations | $| 65.3 |$ | 64.5 | | Net income (loss) (millions) | $| (341.9) |$ | 653.2 | | Income (loss) per diluted share | $| (12.70) |$ | 23.34 | Bio-Rad Reports Third-Quarter 2025 Financial Results HERCULES, Calif.—October 29, 2025 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a ...